Protocol Specific Research

科学的许多方面的进步，包括分子生物学、基因组学和蛋白质组学，导致了 在确定癌症的病因和新的治疗方法方面取得了重大进展。需要密切合作 将实验室的先进技术带入临床。这些协作和资源可用于进行 转化型临床研究在当前的资助期非常有成效。目前， CCSG为0.25 FTE研究护士和0.5 FTE临床研究专家(CRS)提供资金。这些Iu 西蒙癌症中心已经通过下面详细描述的程序分配了这笔资金，以支持发起的研究 第一阶段和试点研究是非常有价值的。ID Simon癌症中心还提供了 从其他来源获得的额外资金，用于进行这些试验。我们预计会有越来越多的患者 计入未来第一阶段和试点研究，因为在本供资期间征聘 转化型临床研究人员(Chiorean、Farag、Hahn和Matei)和我们第一阶段的扩展计划 计划在下一个资助期。 从2004年到2007年年中，IUSCC通过这一机制支持了15项临床试验。患者应计总金额 是132年前。有时，该中心会使用额外的资金来支持个别试验。例如, IUSCC的额外资金已用于支持与试验有关的实验室相关研究 在PSR机制的支持下；PSR资金已用于支持护士和临床研究 专家。这一进程已在本周期进行了更新，从而增加了教职员工人数 进行由调查员发起的试验。PSR支持已优先用于将生成 已用于(或将用于)支持R21快速试验和其他同行评审资金的初步数据 申请。 2006年更新了为开展试点临床试验寻求资金的程序，并向所有人提供 通过在http://cancer.iu.edu/research/fundinq/clin trial.php上找到的连续RFA，IUCC成员。这个 公告详细说明了这样一个事实，即议定书特定研究资金涵盖了一个核心小组的 研究护士和数据经理(临床研究专家)，用于进行高优先级、创新、 可行性或原则验证性临床试验。资金申请将用于 用于预防或治疗癌症的候选试剂或装置。申请被接收和审查 由临床研究委员会每月出版。

Advances in many aspects of science including molecular biology, genomics and proteomics have resulted in significant advances in defining the causes of and new treatments for cancer. Close collaborations are needed to take advances from the laboratory into the clinic. These collaborations and resources available to conduct translational clinical research have been very productive during the current funding period. Currently, the CCSG provides funding for 0.25 FTE research nurse and 0.5 FTE clinical research specialist (CRS). The IU Simon Cancer Center has allocated this money by a process described in detail below to support investigatorinitiated Phase I and pilot studies that are highly meritorious. The ID Simon Cancer Center also provided additional funds from other sources for the conduct of these trials. We anticipate growing numbers of patients accrued to future phase I and pilot studies because of the recruitment during the current funding period of translational clinical investigators (Chiorean, Farag, Hahn, and Matei) and planned expansion of our phase I program during the next funding period. From 2004 through mid-2007, the IUSCC supported 15 clinical trials by this mechanism. Total patient accrual is to date 132. On occasion, the Center used additional funds to support individual trials. For example, additional IUSCC funds have been used to support the laboratory correlative studies associated with a trial supported by the PSR mechanism; the PSR funding has been used to support nurses and clinical research specialists. The process has been updated during the current cycle with resulting increased number of faculty conducting investigator-initiated trials. PSR support has been prioritized to protocols that will generate preliminary data that has been (or will be) used to support R21 Quick Trials and other peer-reviewed funding applications. The process to seek funding for the conduct of pilot clinical trials was updated in 2006 and is available to all IUCC members via a continuous RFA found at http://cancer.iu.edu/research/fundinq/clin trial.php. The announcement details the fact that Protocol Specific Research funding covers the cost of a core group of research nurses and data managers (clinical research specialists) for the conduct of high priority, innovative, feasibility or proof-of-principle clinical trials. The requests for funding are to be used for early-phase testing of a candidate agent or device for the prevention or treatment of cancer. Applications are received and reviewed monthly by the Clinical Research Committee.